Literature DB >> 22639114

Expert opinion: future frontiers and challenges in cancer medicine.

Patrick G Johnston1, Mark Lawler.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22639114      PMCID： PMC3360916          DOI： 10.1634/theoncologist.2012-0210

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  14 in total

1.  The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Authors:  Jennifer E Joh; Nicole N Esposito; John V Kiluk; Christine Laronga; M Catherine Lee; Loretta Loftus; Hatem Soliman; Judy C Boughey; Carol Reynolds; Thomas J Lawton; Peter I Acs; Lucio Gordan; Geza Acs
Journal:  Oncologist       Date:  2011-10-20

2.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Authors:  C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski
Journal:  Ann Oncol       Date:  2011-01-12       Impact factor: 32.976

3.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

4.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Andrew Grigg; Chris Arthur; Kerry Taylor; Richard Herrmann; Kevin P Lynch; Timothy P Hughes
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

5.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

7.  Converting a breast cancer microarray signature into a high-throughput diagnostic test.

Authors:  Annuska M Glas; Arno Floore; Leonie J M J Delahaye; Anke T Witteveen; Rob C F Pover; Niels Bakx; Jaana S T Lahti-Domenici; Tako J Bruinsma; Marc O Warmoes; René Bernards; Lodewyk F A Wessels; Laura J Van't Veer
Journal:  BMC Genomics       Date:  2006-10-30       Impact factor: 3.969

8.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Authors:  Christina Curtis; Sohrab P Shah; Suet-Feung Chin; Gulisa Turashvili; Oscar M Rueda; Mark J Dunning; Doug Speed; Andy G Lynch; Shamith Samarajiwa; Yinyin Yuan; Stefan Gräf; Gavin Ha; Gholamreza Haffari; Ali Bashashati; Roslin Russell; Steven McKinney; Anita Langerød; Andrew Green; Elena Provenzano; Gordon Wishart; Sarah Pinder; Peter Watson; Florian Markowetz; Leigh Murphy; Ian Ellis; Arnie Purushotham; Anne-Lise Børresen-Dale; James D Brenton; Simon Tavaré; Carlos Caldas; Samuel Aparicio
Journal:  Nature       Date:  2012-04-18       Impact factor: 49.962

9.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Authors:  Philipp le Coutre; Oliver G Ottmann; Francis Giles; Dong-Wook Kim; Jorge Cortes; Norbert Gattermann; Jane F Apperley; Richard A Larson; Elisabetta Abruzzese; Stephen G O'Brien; Kazimierz Kuliczkowski; Andreas Hochhaus; Francois-Xavier Mahon; Giuseppe Saglio; Marco Gobbi; Yok-Lam Kwong; Michele Baccarani; Timothy Hughes; Giovanni Martinelli; Jerald P Radich; Ming Zheng; Yaping Shou; Hagop Kantarjian
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113

10.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Authors:  Thomas O'Hare; William C Shakespeare; Xiaotian Zhu; Christopher A Eide; Victor M Rivera; Frank Wang; Lauren T Adrian; Tianjun Zhou; Wei-Sheng Huang; Qihong Xu; Chester A Metcalf; Jeffrey W Tyner; Marc M Loriaux; Amie S Corbin; Scott Wardwell; Yaoyu Ning; Jeffrey A Keats; Yihan Wang; Raji Sundaramoorthi; Mathew Thomas; Dong Zhou; Joseph Snodgrass; Lois Commodore; Tomi K Sawyer; David C Dalgarno; Michael W N Deininger; Brian J Druker; Tim Clackson
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.